Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

5.76

Today's Change

+0.08 (1.40%)

Day's Change

5.20 - 5.76

Trading Volume

2,846,325

Overview

Market Cap

1 Billion

Shares Outstanding

320 Million

Avg Volume

1,925,314

Avg Price (50 Days)

7.32

Avg Price (200 Days)

5.24

PE Ratio

-36.00

EPS

-0.16

Earnings Announcement

22-Nov-2024

Previous Close

5.68

Open

5.50

Day's Range

5.2 - 5.76

Year Range

1.26 - 8.975

Trading Volume

2,846,325

Price Change Highlight

1 Day Change

1.41%

5 Day Change

-7.54%

1 Month Change

-19.55%

3 Month Change

-14.29%

6 Month Change

32.41%

Ytd Change

172.99%

1 Year Change

329.85%

3 Year Change

514.67%

5 Year Change

284.00%

10 Year Change

284.00%

Max Change

284.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment